Liquidia (LQDA) Income towards Parent Company (2020 - 2026)
Liquidia (LQDA) posted quarterly Income towards Parent Company of $52.9 million for Q1 2026, up 237.83% year-over-year from $15.7 million in Q1 2025, and up 263.33% quarter-over-quarter from $14.6 million in Q4 2025.
Liquidia (LQDA) Income towards Parent Company (2020 - 2026) Analysis & Trends
Liquidia's Income towards Parent Company history runs 7 years deep, the most recent figure standing at $52.9 million for Q1 2026.
- In Q1 2026, Income towards Parent Company rose 237.83% year-over-year to $52.9 million; the TTM figure through Mar 2026 stood at -$186.9 million (up 23.86% YoY), while the FY2025 annual figure was -$293.7 million, down 28.44% from the prior year.
- Income towards Parent Company for Q1 2026 stood at $52.9 million, up from $14.6 million in the prior quarter.
- The five-year high for Income towards Parent Company was $52.9 million in Q1 2026, with the low at -$149.9 million in Q3 2025.
- The 5-year median for Income towards Parent Company is -$31.2 million (2023), against an average of -$44.2 million.
- The sharpest annual moves came in 2023 and 2026: Income towards Parent Company sank 435.09% in 2023, then soared 237.83% in 2026.
- Liquidia's Income towards Parent Company stood at -$5.1 million in 2022, then tumbled by 435.09% to -$27.4 million in 2023, then slumped by 40.29% to -$38.5 million in 2024, then soared by 137.8% to $14.6 million in 2025, then surged by 263.33% to $52.9 million in 2026.
- Business Quant data shows LQDA's Income towards Parent Company at $52.9 million in Q1 2026, $14.6 million in Q4 2025, and -$149.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.87 Bn | 42.91 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.00 Bn | 39.35 Bn | 2.15 Bn |
| 3 | Zoetis | 31.59 Bn | 29.92 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - |
| 10 | Liquidia | 6.39 Bn | 6.11 Bn | 160.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 74.70 Mn |
| Mar 31, 2026 | 52.88 Mn |
| Dec 31, 2025 | 14.56 Mn |
| Sep 30, 2025 | -149.91 Mn |
| Jun 30, 2025 | -104.39 Mn |
| Mar 31, 2025 | -38.37 Mn |
| Dec 31, 2024 | -38.51 Mn |
| Sep 30, 2024 | -75.21 Mn |
| Jun 30, 2024 | -93.32 Mn |
| Mar 31, 2024 | -121.96 Mn |
| Dec 31, 2023 | -27.45 Mn |
| Sep 30, 2023 | -31.18 Mn |
| Jun 30, 2023 | -53.03 Mn |
| Mar 31, 2023 | -31.00 Mn |
| Dec 31, 2022 | -5.13 Mn |
| Sep 30, 2022 | -19.38 Mn |
| Jun 30, 2022 | -14.35 Mn |
| Mar 31, 2022 | -15.82 Mn |
| Dec 31, 2021 | -11.47 Mn |
| Sep 30, 2021 | -13.74 Mn |